SEC Form 424B5 filed by Gain Therapeutics Inc.
(To Prospectus Dated June 1, 2022)
EXERCISE OF THE PRE-FUNDED WARRANTS
| | |
PER SHARE
|
| |
PER
PRE-FUNDED WARRANT |
| |
TOTAL
|
| |||||||||
Public offering price
|
| | | $ | 1.35 | | | | | $ | 1.3499 | | | | | $ | 10,999,897.99 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.0945 | | | | | $ | 0.094493 | | | | | $ | 769,992.86 | | |
Proceeds to us, before expenses(2)
|
| | | $ | 1.2555 | | | | | $ | 1.255407 | | | | | $ | 10,229,905.13 | | |
| | |
PAGE
|
| |||
| | | | S-1 | | | |
| | | | S-3 | | | |
| | | | S-5 | | | |
| | | | S-10 | | | |
| | | | S-14 | | | |
| | | | S-15 | | | |
| | | | S-16 | | | |
| | | | S-17 | | | |
| | | | S-25 | | | |
| | | | S-25 | | | |
| | | | S-25 | | | |
| | | | S-26 | | |
| | | | | i | | | |
| | | | | 1 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 15 | | | |
| | | | | 24 | | | |
| | | | | 27 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 31 | | |
|
Public offering price per share
|
| | | | | | | | | $ | 1.35 | | |
|
Net tangible book value per share as of March 31, 2024
|
| | | $ | 0.42 | | | | | | | | |
|
Increase in net tangible book value per share attributable to the offering
|
| | | $ | 0.25 | | | | | | | | |
|
As adjusted net tangible book value per share after giving effect to the offering
|
| | | | | | | | | $ | 0.67 | | |
|
Dilution in net tangible book value per share to new investors
|
| | | | | | | | | $ | (0.68) | | |
UNDERWRITER
|
| |
NUMBER OF
SHARES |
| |
NUMBER OF
PRE-FUNDED WARRANTS |
| ||||||
Titan Partners Group LLC, a division of American Capital Partners, LLC
|
| | | | 7,116,547 | | | | | | 1,031,602 | | |
| | |
Price Per
Share |
| |
Price Per
Pre-Funded Warrant |
| |
Total without
Option |
| |
Total with
Option |
| ||||||||||||
Public offering price
|
| | | $ | 1.35 | | | | | $ | 1.3499 | | | | | $ | 10,999,897.99 | | | | | $ | 12,649,897.69 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.0945 | | | | | $ | 0.09449 | | | | | $ | 769,992.86 | | | | | $ | 885,492.84 | | |
Proceeds, before expenses, to us(2)
|
| | | $ | 1.2555 | | | | | $ | 1.255407 | | | | | $ | 10,229,905.13 | | | | | $ | 11,764,404.85 | | |
Gain Therapeutics, Inc.
4800 Montgomery Lane, Suite 220,
Bethesda, Maryland 20814
(301) 500-1556
Preferred Stock
Debt Securities
Warrants
| | | | | i | | | |
| | | | | 1 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 15 | | | |
| | | | | 22 | | | |
| | | | | 24 | | | |
| | | | | 27 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 31 | | |
Attn: Corporate Secretary
4800 Montgomery Lane, Suite 220,
Bethesda, MD 20814
(301) 500-1556
OF COMMON STOCK
EXERCISE OF THE PRE-FUNDED WARRANTS